MARIA DEL PILAR ESTEVEZ DIZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
conferenceObject Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients not candidates for optimal primary surgery: Safety and effectivenes(2013) MIRANDA, Vanessa Costa; FEDE, Angelo Bezerra de Sousa; ANJOS, Carlos Henrique Dos; SILVA, Juliana Ribeiro da; SANCHEZ, Fernando Barbosa; BESSA, Lyvia Rodrigues da Silva; CARVALHO, Jesus Paula; ABDO FILHO, Elias; FREITAS, Daniela; BARROS, Laryssa Almeida Borges de; SILVA, Samantha Cabral Severino da; ESTEVEZ-DIZ, Maria Del Pilar- Hereditary cancer risk assessment: essential tools for a better approach(2013) GOMY, Israel; DIZ, Maria Del Pilar EstevezHereditary cancer risk assessment (HCRA) is a multidisciplinary process of estimating probabilities of germline mutations in cancer susceptibility genes and assessing empiric risks of cancer, based on personal and family history. It includes genetic counseling, testing and management of at-risk individuals so that they can make well-informed choices about cancer surveillance, surgical treatment and chemopreventive measures, including biomolecular cancer therapies. Providing patients and family members with an appropriate HCRA will contribute to a better process of making decisions about their personal and family risks of cancer. Following individuals at high risk through screening protocols, reassuring those at low risk, and referring those at increased risk of hereditary cancer to a cancer genetics center may be the best suitable approach of HCRA.
conferenceObject Definitive chemoradiotherapy (CRT) for advanced cervical cancer (CC): Should it be different in elderly?(2013) CAIRES, I. Q. S.; CAIRES-LIMA, R.; BARROSO-SOUZA, R.; OLIVEIRA, J. A. De; SOUZA, K. T.; NEGRAO, M. V.; CARVALHO, H.; ABDO FILHO, E.; HOFF, P. M.; DIZ, M. D. P. E.- Infection Related to Implantable Central Venous Access Devices in Cancer Patients: Epidemiology and Risk Factors(2013) FREIRE, Maristela P.; PIERROTTI, Ligia C.; ZERATI, Antonio E.; ARAUJO, Pedro H. X. N.; MOTTA-LEAL-FILHO, J. M.; DUARTE, Laiane P. G.; IBRAHIM, Karim Y.; SOUZA, Antonia A. L.; DIZ, Maria P. E.; PEREIRA, Juliana; HOFF, Paulo M.; ABDALA, EdsonOBJECTIVE. To describe the epidemiology of infections related to the use of implantable central venous access devices (CVADs) in cancer patients and to evaluate measures aimed at reducing the rates of such infections. DESIGN. Prospective cohort study. SETTING. Referral hospital for cancer in Sao Paulo, Brazil. PATIENTS. We prospectively evaluated all implantable CVADs employed between January 2009 and December 2011. Inpatients and outpatients were followed until catheter removal, transfer to another facility, or death. METHODS. Outcome measures were bloodstream infection and pocket infection. We also evaluated the effects that the creation of a multidisciplinary team for CVAD care, avoiding in-hospital implantation of CVADs, and limiting CVAD insertion in neutropenic patients have on the rates of such infections. RESULTS. During the study period, 966 CVADs (mostly venous ports) were implanted in 933 patients, for a combined total of 243,792 catheter-days. We identified 184 episodes of infection: 154 (84%) were bloodstream infections, 21 (11%) were pocket infections, and 9 (5%) were surgical site infections. During the study period, the rate of CVAD-related infection dropped from 2.2 to 0.24 per 1,000 catheter-days (P < .001). Multivariate analysis revealed that relevant risk factors for such infection include surgical reintervention, implantation in a neutropenic patient, in-hospital implantation, use of a cuffed catheter, and nonchemotherapy indication for catheter use. CONCLUSIONS. Establishing a multidisciplinary team specifically focused on CVAD care, together with systematic reporting of infections, appears to reduce the rates of infection related to the use of these devices.
bookPart Tumores do corpo uterino(2013) DIZ, Maria Del Pilar Estevez- Characterization of risk factors in breast cancer young adult patients(2013) ENCINAS, G.; DIZ, M. D. P. E.; LYRA, E. C.; KATAYAMA, M. L. H.; PASINI, F. S.; BRENTANI, M. M.; CHAMMAS, R.; GOES, J. C. G. S.; FOLGUEIRA, M. A. A. K.